



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: Watanabe K. *et al.*

Serial No.: 09/834,596

Filed: April 13, 2001

Title: 2' -or 3'-Hydromethyl Substituted Nucleoside Derivatives for Treatment of Hepatitis Virus Infections

COPY OF PAPERS
ORIGINALLY FILED

JUL 05 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

June 21, 2002


Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed as well as the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,


Kristin Chrudimsky
Reg. No. P-51,561KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-3170(Telephone)
404-572-5145 (Facsimile)




COPY OF PAPERS
ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT
09/834,596

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Kristin Chrudimsky
Reg. No. P-51,561

Date: June 21, 2002

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/834,596
Filing Date	April 13, 2001
First Named Inventor	Watanabe et al.
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	PHA 2020 US

Sheet 1 of 1

RECEIVED
JUN 05 2002
TECH CENTER 1600 2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	6004939		Fletcher TM <i>et al.</i>	12/21/99	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AB	MATSUDA, A. <i>et al.</i> , Chem Abstract Service (online) XP0021192808.	
	AC	MATTHES, E. <i>et al.</i> , <i>Antimicrob. Agents Chemother.</i> 1990, 34(10).	
	AD	MATTHES, E. <i>et al.</i> , <i>Antimicrob. Agents Chemother.</i> 1991, 35(6), 1254-7.	
	AE	MCGUIGAN C. <i>et al.</i> , <i>Antiviral Chemistry & Chemotherapy</i> , vol 5, no. 4, 271-77.	
	AF	TSIBIBOGIN, V.V. <i>et al.</i> , Chem Abstract Service (online), <i>Mol. Biol.</i> 1989, 23(4), 983-7.	
	AG	UEDA, T. <i>et al.</i> , Chem Abstract Service (online) XP002192807.	
	AH	VICTOROVA, L. S. <i>et al.</i> , <i>Nucleosides and Nucleotides</i> , vol. 15, nos. 1-3, 1996, 655- 667.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.